Governor Ron DeSantis Announces New Monoclonal Antibody Site in Brevard County
MERRITT ISLAND, Fla. – Today, Governor Ron DeSantis announced that the State of Florida is setting up a new monoclonal antibody therapy treatment site in Merritt Island at Kiwanis Island Park. This location has the capacity to serve more than 300 patients per day and will be open every day from 9 a.m. to 7 p.m.
“Since we began expanding access to monoclonal antibody treatment sites in Florida, there have been more and more people asking about these therapies,” said Governor Ron DeSantis. “Today, I am proud to continue the momentum and announce the opening of an additional monoclonal antibody treatment site in Brevard County. Monoclonals are safe and have proven to significantly reduce the chance that somebody ends up being hospitalized for COVID.”
Kiwanis Island Park
951 Kiwanis Island Park Road
Merritt Island, Florida 32952
Hours: 7 days a week, 9:00 AM – 7:00 PM
Jacksonville Public Library
304 North Main Street
Jacksonville, Florida 32202
Hours: 7 days a week, 9:00 AM – 5:00 PM
Camping World Stadium
1 Citrus Bowl Place
Orlando, Florida 32805
Hours: 7 days a week, 9:00 AM – 7:00 PM
Monoclonal antibody treatments can be prescribed by health care providers to individuals 12 years of age and older who have been diagnosed with COVID-19 or who have been exposed to someone with COVID-19 and are at high risk for severe illness and hospitalization. However, at Governor DeSantis’ direction, there is currently a standing order in Florida signed by the State Surgeon General that allows patients to receive this treatment without a prescription or referral if administered by an eligible health care provider. Such referrals are not required at any of the State of Florida monoclonal antibody treatment sites and treatments are available at no cost to patients.
###
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.